The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes
Open accessAbstract
An important goal of biomedical research is to translate basic research findings into useful medical advances. In the field of neuropharmacology this requires understanding disease mechanisms as well as the effects of drugs and other compounds on neuronal function. Our hope is that this information will result in new or improved treatment for CNS disease. Despite great progress in our understanding of the structure and functions of the CNS, the discovery of new drugs and their clinical development for many CNS disorders has been problematic. As a result, CNS drug discovery and development programs have been subjected to significant cutbacks and eliminations over the last decade. While there has been recent resurgence of interest in CNS targets, these past changes in priority of the pharmaceutical and biotech industries reflect several well‐documented realities. CNS drugs in general have higher failure rates than non‐CNS drugs, both preclinically and clinically, and in some areas, such as the major neurodegenerative diseases, the clinical failure rate for disease‐modifying treatments has been 100%. The development times for CNS drugs are significantly longer for those drugs that are approved, and post‐development regulatory review is longer. In this introduction we review some of the reasons for failure, delineating both scientific and technical realities, some unique to the CNS, that have contributed to this. We will focus on major neurodegenerative disorders, which affect millions, attract most of the headlines, and yet have witnessed the fewest successes. We will suggest some changes that, when coupled with the approaches discussed in the rest of this special volume, may improve outcomes in future CNS‐targeted drug discovery and development efforts. This article is part of the Special Issue entitled “Beyond small molecules for neurological disorders”. HighlightsCNS drug discovery and development has been problematic, particularly in the area of acute and chronic neurodegenerative disorders.These difficulties have resulted in significant cutbacks in CNS drug programs.Drug targets must be better understood in terms of their role in normal CNS function and in disease.Animal models of disease and hypothetical drug regimens must better reflect the clinical condition.Unique combinations may have to be tested, including combinations of drugs which have not independently demonstrated efficacy.Clinical trials may have to be much longer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Nährlich, L., Mainz, J. G., Adams, C., Engel, C., Herrmann, G., Icheva, V., Lauer, J., Deppisch, C., Wirth, A., Unger, K., et al. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350071 · Cited by 2,525
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Animal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Feigin, V. L., Lawes, C. M., Bennett, D. A., & Anderson, C. S. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00266-7 · Cited by 1,932 · cited 1×
“Stroke is primarily a disease of the aged, and is the second leading cause of death in the world (slightly less in developed countries), with approximately half of all stroke sufferers dying within the first year (Feigin et al., 2003).”
Pathophysiology of traumatic brain injury
Werner, C., & Engelhard, K. (2007) · British Journal of Anaesthesia · doi:10.1093/bja/aem131 · Cited by 1,712
Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
Rácz, I., & Zimmer, A. (2006) · Standards of Mouse Model Phenotyping · doi:10.1002/9783527611942.ch9 · Cited by 1,659
Le Bars, D., Gozariu, M., & Cadden, S. W. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01514-x · Cited by 1,459 · cited 1×
“…conditions mimicking many aspects of their human disease counterparts, have seldom proven predictive to this point (Bird and Parlee, 2000; Branchi et al., 2003; Cernak, 2005; Gamzu, 1985; le Bars et al., 2001; McGonigle, 2014; Petters and Sommer, 2000; Tordjman et al., 2007; Windisch, 2014).”
The validity of animal models of depression
Willner, P. (1984) · Psychopharmacology · doi:10.1007/bf00427414 · Cited by 1,409
Changing patterns in the epidemiology of traumatic brain injury
Roozenbeek, B., Maas, A. I. R., & Menon, D. K. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.22 · Cited by 1,368
Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.541128 · Cited by 1,352
Frequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447.pub3 · Cited by 1,058
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R., Mitchell, J., Lyon, M., & Moore, D. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447 · Cited by 909
del Zoppo, G. J., Saver, J. L., Jauch, E. C., & Adams, H. P. (2009) · Stroke · doi:10.1161/strokeaha.109.192535 · Cited by 829
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679
Presymptomatic hippocampal atrophy in Alzheimer's disease: A longitudinal MRI study
Fox, N. C., Warrington, E. K., Freeborough, P. A., Hartikainen, P., Kennedy, A. M., Stevens, J. M., & Rossor, M. N. (1996) · Brain · doi:10.1093/brain/119.6.2001 · Cited by 656
Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year
Kwiatkowski, T. G., Libman, R. B., Frankel, M., Tilley, B. C., Morgenstern, L. B., Lu, M., Broderick, J. P., Lewandowski, C. A., Marler, J. R., Levine, S. R., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402302 · Cited by 647
Identification of normal and pathological aging in prospectively studied nondemented elderly humans
Dickson, D. W., Crystal, H. A., Mattiace, L. A., Masur, D. M., Blau, A. D., Davies, P., Yen, S.-H., & Aronson, M. K. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90027-u · Cited by 643
Gladstone, D. J., Black, S. E., & Hakim, A. M. (2002) · Stroke · doi:10.1161/01.str.0000025518.34157.51 · Cited by 635
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
Design, power, and interpretation of studies in the standard murine model of ALS
Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., Bostrom, A., Theodoss, J., Al‐Nakhala, B. M., Vieira, F. G., et al. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960701856300 · Cited by 504
The roles of K+ channels in cancer
Pardo, L. A., & Stühmer, W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3635 · Cited by 477
Cernak, I. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.410 · Cited by 462
The Cystic Fibrosis Transmembrane Conductance Regulator
Riordan, J. R. (1993) · Annual Review of Physiology · doi:10.1146/annurev.ph.55.030193.003141 · Cited by 446
Dal Canto, M. C., & Gurney, M. E. (1995) · Brain Research · doi:10.1016/0006-8993(95)00063-v · Cited by 435
Brown, C. R., Hong-Brown, L. Q., Biwersi, J., Verkman, A. S., & Welch, W. J. (1996) · Cell Stress & Chaperones · doi:10.1379/1466-1268(1996)001<0117:ccctmp>2.3.co;2 · Cited by 417
Olivares, D., K. Deshpande, V., Shi, Y., K. Lahiri, D., H. Greig, N., T. Rogers, J., & Huang, X. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322564 · Cited by 407
The Blood–Brain Barrier and Epilepsy
Oby, E., & Janigro, D. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00817.x · Cited by 388
Neuroprotection for ischemic stroke: Two decades of success and failure
Cheng, Y. D., Al-Khoury, L., & Zivin, J. A. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.36 · Cited by 384
Patterns of Cognitive Decline in Presymptomatic Alzheimer Disease: A Prospective Community Study
Chen, P., Ratcliff, G., Belle, S. H., Cauley, J. A., DeKosky, S. T., & Ganguli, M. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.9.853 · Cited by 369
Lost in translation: Treatment trials in the SOD1 mouse and in human ALS
Benatar, M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.015 · Cited by 350
Willner, P. (1986) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(86)90051-5 · Cited by 346
Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels
Gribkoff, V. K., Starrett, J. E., Dworetzky, S. I., Hewawasam, P., Boissard, C. G., Cook, D. A., Frantz, S. W., Heman, K., Hibbard, J. R., Huston, K., et al. (2001) · Nature Medicine · doi:10.1038/86546 · Cited by 311
Self-citationEckford, P. D. W., Li, C., Ramjeesingh, M., & Bear, C. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.393637 · Cited by 309
Traumatic brain injury: Can the consequences be stopped?
Park, E., Bell, J. D., & Baker, A. J. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080282 · Cited by 300
Evaluation of animal models of neurobehavioral disorders
van der Staay, F. J., Arndt, S. S., & Nordquist, R. E. (2009) · Behavioral and Brain Functions · doi:10.1186/1744-9081-5-11 · Cited by 296
Is Pharma Running Out of Brainy Ideas?
Miller, G. (2010) · Science · doi:10.1126/science.329.5991.502 · Cited by 284 · cited 1×
“The failure rate for new drugs targeting important central nervous system (CNS) diseases is very high relative to most other areas of drug discovery, a fact reflected in the many pharmaceutical company CNS programs that have been disbanded or significantly reduced (Abbott, 2011; Miller, 2010).”
Götz, J., Streffer, J. R., David, D., Schild, A., Hoerndli, F., Pennanen, L., Kurosinski, P., & Chen, F. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001508 · Cited by 274
Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack
Brown, M. R., Kronengold, J., Gazula, V.-R., Chen, Y., Strumbos, J. G., Sigworth, F. J., Navaratnam, D., & Kaczmarek, L. K. (2010) · Nature Neuroscience · doi:10.1038/nn.2563 · Cited by 260
Self-citationTrends in Acute Ischemic Stroke Trials Through the 20th Century
Kidwell, C. S., Liebeskind, D. S., Starkman, S., & Saver, J. L. (2001) · Stroke · doi:10.1161/01.str.32.6.1349 · Cited by 246
Excitotoxic mechanisms in stroke: An update of concepts and treatment strategies
HAZELL, A. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.026 · Cited by 238
Besancon, E., Guo, S., Lok, J., Tymianski, M., & Lo, E. H. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.02.003 · Cited by 231
Animal models in the drug discovery pipeline for Alzheimer's disease
Van Dam, D., & De Deyn, P. P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01299.x · Cited by 229
Transgenic models of Alzheimer’s disease: Learning from animals
Spires, T. L., & Hyman, B. T. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.423 · Cited by 212
Non-conducting functions of voltage-gated ion channels
Kaczmarek, L. K. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1988 · Cited by 195
Self-citationJoiner, W. J., Tang, M. D., Wang, L.-Y., Dworetzky, S. I., Boissard, C. G., Gan, L., Gribkoff, V. K., & Kaczmarek, L. K. (1998) · Nature Neuroscience · doi:10.1038/2176 · Cited by 190
Self-citationFisher, M. (2003) · Stroke · doi:10.1161/01.str.0000072983.64326.53 · Cited by 188
Cystic Fibrosis Transmembrane Regulator Correctors and Potentiators
Rowe, S. M., & Verkman, A. S. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009761 · Cited by 176
Behavioural models in psychopharmacology : theoretical, industrial, and clinical perspectives
Willner, P. (1990) · Cambridge University Press eBooks · Cited by 173
Slack, Slick, and Sodium-Activated Potassium Channels
Kaczmarek, L. K. (2013) · ISRN Neuroscience · doi:10.1155/2013/354262 · Cited by 170
Self-citationEffects of channel modulators on cloned large-conductance calcium-activated potassium channels.
Gribkoff, V. K., Lum-Ragan, J. T., Boissard, C. G., Post-Munson, D. J., Meanwell, N. A., Starrett, J. E., Kozlowski, E. S., Romine, J. L., Trojnacki, J. T., Mckay, M. C., et al. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09145-x · Cited by 167
Self-citationAnimal Models Relevant to Schizophrenia and Autism: Validity and Limitations
Tordjman, S., Drapier, D., Bonnot, O., Graignic-Philippe, R., Fortes, S., Cohen, D., Millet, B., Laurent‐Levinson, C., & Roubertoux, P. L. (2006) · Behavior Genetics · doi:10.1007/s10519-006-9120-5 · Cited by 160
Modeling psychiatric disorders for developing effective treatments
Kaiser, T., & Feng, G. (2015) · Nature Medicine · doi:10.1038/nm.3935 · Cited by 157
Animal models of depression: are there any?
O'Neil, M. F., & Moore, N. A. (2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.496 · Cited by 157
Animal models of CNS disorders
McGonigle, P. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.016 · Cited by 156
Multiple sclerosis: New insights and trends
Koriem, K. M. M. (2016) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2016.03.009 · Cited by 149
Time Course and Predictors of Neurological Deterioration After Intracerebral Hemorrhage
Lord, A. S., Gilmore, E. J., Choi, H., & Mayer, S. A. (2015) · Stroke · doi:10.1161/strokeaha.114.007704 · Cited by 148
Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.007 · Cited by 147
Philip, M., Benatar, M. G., Fisher, M., & Savitz, S. I. (2008) · Stroke · doi:10.1161/strokeaha.108.524330 · Cited by 137
Strumbos, J. G., Brown, M. R., Kronengold, J., Polley, D. B., & Kaczmarek, L. K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1125-10.2010 · Cited by 135
Self-citationThe evolution of acute stroke recorded by multimodal magnetic resonance imaging
Quast, M. J., Huang, N., Hillman, G. R., & Kent, T. A. (1993) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(93)90465-p · Cited by 129
Excitatory amino acid antagonists for acute stroke
Muir, K. W., & Lees, K. R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001244 · Cited by 124
Current and emerging therapies in multiple sclerosis: a systematic review
Castro-Borrero, W., Graves, D. F., Frohman, T. C., Flores, A., Hardeman, P., Logan, D., Orchard, M., Greenberg, B. M., & Frohman, E. M. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612450936 · Cited by 122
Neuroprotection and stroke: time for a compromise
Young, A. R., Ali, C., Duretete, A., & Vivien, D. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04866.x · Cited by 118
Does long term use of psychiatric drugs cause more harm than good?
Gøtzsche, P. C., Young, A. H., & Crace, J. (2015) · BMJ · doi:10.1136/bmj.h2435 · Cited by 111
Multiple sclerosis - remyelination failure as a cause of disease progression.
Hagemeier, K., Brück, W., & Kuhlmann, T. (2012) · PubMed · doi:10.14670/hh-27.277 · Cited by 108
Copen, W. A., Schwamm, L. H., González, R., Wu, O., Harmath, C. B., Schaefer, P. W., Koroshetz, W. J., & Sorensen, A. G. (2001) · Radiology · doi:10.1148/radiol.2211001397 · Cited by 107
The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel
Gribkoff, V. K., Champigny, G., Barbry, P., Dworetzky, S. I., Meanwell, N. A., & Lazdunski, M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)78079-x · Cited by 104
Self-citationGrupke, S. L., Hall, J., Dobbs, M., Bix, G. J., & Fraser, J. F. (2014) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2014.11.013 · Cited by 102
Autoimmunity in multiple sclerosis
Keyser, J. D. (1988) · Neurology · doi:10.1212/wnl.38.3.371 · Cited by 100
Pharmacological activation and inhibition of Slack (Slo2.2) channels
Yang, B. V., Gribkoff, V. K., Pan, J., et al. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.06.003 · Cited by 99
Self-citationNovartis to shut brain research facility
Abbott, A. (2011) · Nature · doi:10.1038/480161a · Cited by 96
Behavioural Models in Psychopharmacology
&NA; (1991) · International Clinical Psychopharmacology · doi:10.1097/00004850-199100640-00006 · Cited by 96
Radad, K., Gille, G., & Rausch, W. (2005) · PubMed · Cited by 95
Recent advances in the pharmacological management of acute and chronic pain.
Schug, S. A., & Goddard, C. (2014) · UWA Profiles and Research Repository (UWA) · doi:10.3978/j.issn.2224-5820.2014.10.02 · Cited by 95
Markus, R., Reutens, D. C., Kazui, S., Read, S. J., Wright, P., Chambers, B. R., Sachinidis, J. I., Tochon‐Danguy, H., & Donnan, G. A. (2003) · Stroke · doi:10.1161/01.str.0000094422.74023.ff · Cited by 94
The 2007 Feinberg Lecture: A New Road Map for Neuroprotection
Donnan, G. A. (2007) · Stroke · doi:10.1161/strokeaha.107.493296 · Cited by 94
Current and Future Therapies for Multiple Sclerosis
Minagar, A. (2013) · Scientifica · doi:10.1155/2013/249101 · Cited by 92
Farrimond, L. E., Roberts, E., & McShane, R. H. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-000917 · Cited by 92
Identifying and utilizing the ischemic penumbra
Fisher, M., & Baştan, B. (2012) · Neurology · doi:10.1212/wnl.0b013e3182695814 · Cited by 91
Conn, P. J., & Roth, B. L. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301638 · Cited by 90
Panza, F., Solfrizzi, V., Imbimbo, B. P., & Logroscino, G. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.935332 · Cited by 87
Duration of Neuroprotective Treatment for Ischemic Stroke
Dyker, A. G., & Lees, K. R. (1998) · Stroke · doi:10.1161/01.str.29.2.535 · Cited by 86
Cheney, J. A., Weisser, J. D., Bareyre, F. M., Laurer, H. L., Saatman, K. E., Raghupathi, R., Gribkoff, V. K., Starrett, J. E., & McIntosh, T. K. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200104000-00008 · Cited by 74
Self-citationSuccesses and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease
Berk, C., & Sabbagh, M. N. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0108-6 · Cited by 70
Memantine ER/Donepezil: A Review in Alzheimer’s Disease
Greig, S. L. (2015) · CNS Drugs · doi:10.1007/s40263-015-0287-2 · Cited by 69
Broadstock, M., Ballard, C. G., & Corbett, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.936848 · Cited by 63
Transgenic animals as models for human disease
Petters, R. M., & Sommer, J. R. (2000) · Transgenic Research · doi:10.1023/a:1008926303533 · Cited by 58
Animal models of mental retardation: from gene to cognitive function
Branchi, I., Bichler, Z., Berger-Sweeney, J. E., & Ricceri, L. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(03)00016-2 · Cited by 55
Kv3.3 potassium channels and spinocerebellar ataxia
Zhang, Y., & Kaczmarek, L. K. (2015) · The Journal of Physiology · doi:10.1113/jp271343 · Cited by 53
Self-citationBuilding a roadmap for developing combination therapies for Alzheimer’s disease
Perry, D. P., Sperling, R. A., Katz, R. G., Berry, D. A., Dilts, D. M., Hanna, D. L., Salloway, S., Trojanowski, J. Q., Bountra, C., Krams, M., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.996551 · Cited by 53
Self-citationThe therapeutic potential of neuronal KV7 (KCNQ) channel modulators: an update
Gribkoff, V. K. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.5.565 · Cited by 52
Self-citationTranslating promising preclinical neuroprotective therapies to human stroke trials
Cook, D. J., & Tymianski, M. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.34 · Cited by 51
Recent developments in clinical trials for the treatment of traumatic brain injury
Stein, D. G., Geddes, R. I., & Sribnick, E. A. (2015) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52892-6.00028-3 · Cited by 47
Genentech's Alzheimer's antibody trial to study disease prevention
Garber, K. (2012) · Nature Biotechnology · doi:10.1038/nbt0812-731 · Cited by 47
Potassium channel modulation and auditory processing
Brown, M. R., & Kaczmarek, L. K. (2011) · Hearing Research · doi:10.1016/j.heares.2011.03.004 · Cited by 46
Self-citationDissociable processes underlying decisions in the Iowa Gambling Task: a new integrative framework
Stocco, A., Fum, D., & Napoli, A. (2009) · Behavioral and Brain Functions · doi:10.1186/1744-9081-5-1 · Cited by 46
Animal Behavioral Models in the Discovery of Compounds To Treat Memory Dysfunction
Gamzu, E. R. (1985) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1985.tb37602.x · Cited by 44
Disease Modification in Parkinsonʼs Disease
Henchcliffe, C., & Severt, W. (2011) · Drugs & Aging · doi:10.2165/11591320-000000000-00000 · Cited by 44
Riluzole: A New Agent for Amyotrophic Lateral Sclerosis
Wagner, M., & Landis, B. E. (1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100614 · Cited by 42
Drug Combinations in the Treatment of Neuropathic Pain
Eisenberg, E., & Suzan, E. (2014) · Current Pain and Headache Reports · doi:10.1007/s11916-014-0463-y · Cited by 40
Champigny, G., Imler, J., Puchelle, É., Dalemans, W., Gribkoff, V. K., Hinnrasky, J., Dott, K., Barbry, P., Pavirani, A., & Lazdunski, M. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07239.x · Cited by 39
Self-citationDosing of antipsychotics in schizophrenia across the life-spectrum
Uchida, H., & Mamo, D. C. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.04.023 · Cited by 38
Novel concepts in excitotoxic neurodegeneration after stroke
Aarts, M. M., Arundine, M., & Tymianski, M. (2003) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399403007087 · Cited by 36
Memantine Extended Release (28 mg Once Daily): A Review of Its Use in Alzheimer’s Disease
Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0400-3 · Cited by 32
Drugs and clinical trials in neurodegenerative diseases.
Stanzione, P., & Tropepi, D. (2011) · PubMed · doi:10.4415/ann_11_01_11 · Cited by 30
Reviewing the Role of Donepezil in the Treatment of Alzheimer’s Disease
Doody, R. S., Cummings, J. L., & Farlow, M. R. (2012) · Current Alzheimer Research · doi:10.2174/156720512802455412 · Cited by 29
Neuroprotection of Acute Ischemic Stroke: Where are We?
Fisher, M. (1999) · The Neuroscientist · doi:10.1177/107385849900500614 · Cited by 29
Screening of antipsychotic drugs in animal models
Weiner, I., Gaisler, I., Schiller, D., Green, A., Zuckerman, L., & Joel, D. (2000) · Drug Development Research · Cited by 26
Why is publication of negative clinical trial data important?
Hayes, A. G., & Hunter, J. A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02215.x · Cited by 20
Windisch, M. (2014) · Neurodegenerative Diseases · doi:10.1159/000357568 · Cited by 18
Half of US clinical trials go unpublished
Jones, N. (2013) · Nature · doi:10.1038/nature.2013.14286 · Cited by 17
d’Esterre, C. D., Aviv, R. I., & Lee, T. (2012) · Acta Radiologica · doi:10.1258/ar.2012.110582 · Cited by 15
Substance P (NK1) Receptor Antagonists—Analgesics or Not?
Boyce, S., & Hill, R. G. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18891-6_13 · Cited by 15
Future Viable Models of Psychiatry Drug Discovery in Pharma
Rizzo, S. J. S., Edgerton, J. R., Hughes, Z. A., & Brandon, N. J. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113475871 · Cited by 14
Of mice and men (and women and children): Scientific and ethical implications of animal models
Bird, S. J., & Parlee, M. B. (2000) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(00)00139-1 · Cited by 11
Neuroimaging Trends and Future Outlook
Fritz, J. V. (2013) · Neurologic Clinics · doi:10.1016/j.ncl.2013.07.007 · Cited by 10
Where will the (New) Drugs for Traumatic Brain Injury Treatment be Coming From?
Agoston, D. V., & Risling, M. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00027 · Cited by 6
Cited by
Alzheimer’s disease drug development pipeline: 2022
Cummings, J., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Fonseca, J., & Taghva, K. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12295 · Cited by 665
Human biomimetic liver microphysiology systems in drug development and precision medicine
Gough, A., Soto-Gutierrez, A., Vernetti, L., Ebrahimkhani, M. R., Stern, A. M., & Taylor, D. L. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00386-1 · Cited by 117
Jiménez-Garrido, D. F., Gómez-Sousa, M., Ona, G., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-61169-x · Cited by 110
Greenway, K. T., Garel, N., Jerome, L., & Feduccia, A. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1772054 · Cited by 94
Roberts, A. C., & Clarke, H. F. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902288116 · Cited by 79
Metadata
- Authors
- Gribkoff, V. K., & Kaczmarek, L. K.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 120
- Pages
- 11-19
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2299350316
- Cited by
- 371
- References
- 122
- FWCI
- 11.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.